|
Cancer type | Therapy | Phase | Status | Protocol ID |
|
Relapsed and refractory multiple myeloma | Cyclophosphamide and pulse dexamethasone with hydroxychloroquine or rapamycin | 0 | Completed | NCT01396200 |
|
Glioblastoma multiforme | Hydroxychloroquine, radiation, and temozolimide | I, II | Closed | NCT00486603 |
|
Pancreas adenocarcinoma | Hydroxychloroquine, gemcitabine | I, II | Closed | NCT01128296 |
|
Prostate cancer | Hydroxychloroquine after prostate cancer treatment | II | Closed | NCT00726596 |
|
Non-small cell lung cancer | Erlotinib with or without hydroxychloroquine | II | Closed | NCT00977470 |
|
Metastatic pancreatic cancer | Hydroxychloroquine after prostate cancer treatment | II | Closed | NCT01273805 |
|
Relapsed and refractory multiple myeloma | Chloroquine, bortezomib, and cyclophosphamide | II | Closed | NCT01438177 |
|
Advanced solid tumors irresponsive to chemotherapy | Hydroxychloroquine, sunitinib | I | Closed | NCT00813423 |
|
B-cell chronic lymphocytic leukemia | Hydroxychloroquine | II | Temporarily Closed | NCT00771056 |
|
Surgery removable Stage III or Stage IV melanoma | Hydroxychloroquine | 0 | Temporarily Closed | NCT00962845 |
|
Relapsed and refractory multiple myeloma | Hydroxychloroquine, bortezomib | I, II | Active | NCT00568880 |
|
Lung cancer | Hydroxychloroquine, gefitinib | I, II | Active | NCT00809237 |
|
Ductal carcinoma in situ | Chloroquine | I, II | Active | NCT01023477 |
|
Colorectal cancer | Hydroxychloroquine, folinic acid, 5-fluorouracil, oxaliplatin, and bevacizumab | I, II | Active | NCT01206530 |
|
Pancreatic cancer | Hydroxychloroquine, protein-bound paclitaxel, and gemcitabine | I, II | Active | NCT01506973 |
|
Previously treated renal cell carcinoma | Hydroxychloroquine, everolimus | I, II | Active | NCT01510119 |
|
Renal cell carcinoma | Hydroxychloroquine, aldesleukin | I, II | Active | NCT01550367 |
|
Unresectable hepatocellular carcinoma | Hydroxychloroquine, transarterial chemoembolization (TACE) | I, II | Active | NCT02013778 |
|
Metastatic colorectal cancer | Hydroxychloroquine, capecitabine, oxaliplatin, and bevacizumab | II | Active | NCT01006369 |
|
Chronic myeloid leukemia | Imatinib mesylate with or without hydroxychloroquine | II | Active | NCT01227135 |
|
Breast cancer | Hydroxychloroquine | II | Active | NCT01292408 |
|
Advanced or metastatic breast cancer | Chloroquine, taxane | II | Active | NCT01446016 |
|
Resectable pancreatic cancer | Hydroxychloroquine, capecitabine, and radiation | II | Active | NCT01494155 |
|
High grade gliomas | Hydroxychloroquine, radiation | II | Active | NCT01602588 |
|
Advanced/recurrent non-small cell lung cancer | Hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab | II | Active | NCT01649947 |
|
Progressive metastatic castrate refractory prostate cancer | Navitoclax, abiraterone acetate with or without hydroxychloroquine | II | Active | NCT01828476 |
|
Soft tissue sarcoma | Hydroxychloroquine, rapamycin | II | Active | NCT01842594 |
|
Potentially resectable pancreatic cancer | Protein-bound paclitaxel, gemcitabine with or without hydroxychloroquine | II | Active | NCT01978184 |
|
Metastatic or unresectable solid tumors | Hydroxychloroquine, temozolomide | I | Active | NCT00714181 |
|
Irresponsive metastatic solid tumors | Hydroxychloroquine, temsirolimus | I | Active | NCT00909831 |
|
Stage IV small cell lung cancer | Chloroquine | I | Active | NCT00969306 |
|
Advanced solid tumors | Hydroxychloroquine, vorinostat | I | Active | NCT01023737 |
|
Primary renal cell carcinoma | Hydroxychloroquine before surgery | I | Active | NCT01144169 |
|
Advanced cancer | Hydroxychloroquine sirolimus, or vorinostat | I | Active | NCT01266057 |
|
Solid tumors | Hydroxychloroquine, radiation | I | Active | NCT01417403 |
|
Melanoma | Chloroquine, radiation, DT01 | I | Active | NCT01469455 |
|
Advanced solid tumors, melanoma, prostate, or kidney cancer | Hydroxychloroquine, Akt inhibitor MK2206 | I | Active | NCT01480154 |
|
Stages I–III small cell lung cancer | Chloroquine, radiation | I | Active | NCT01575782 |
|
Refractory or relapsed solid tumors | Hydroxychloroquine, sorafenib | I | Active | NCT01634893 |
|
Lymphangioleiomyomatosis in women | Hydroxychloroquine sirolimus | I | Active | NCT01687179 |
|
Relapsed or refractory multiple myeloma | Hydroxychloroquine, cyclophosphamide, dexamethasone, and sirolimus | I | Active | NCT01689987 |
|
Nonresectable pancreatic adenocarcinoma | Chloroquine, gemcitabine | I | Active | NCT01777477 |
|
BRAF mutant metastatic melanoma | Hydroxychloroquine, vemurafenib | I | Active | NCT01897116 |
|
Advanced solid tumors | Chloroquine, carboplatin, and gemcitabine | I | Active | NCT02071537 |
|
Brain metastasis | Chloroquine, radiation | 0 | Active | NCT01727531 |
|